N4 Pharma launch Interactive Investor Hub

N4 Pharma plc
[shareaholic app="share_buttons" id_name="post_below_content"]

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced the launch of the N4 Pharma Interactive Investor Hub. For both existing and prospective shareholders, the new Investor Hub brings all N4 Pharma content into a single integrated platform to better inform and engage with investors and stakeholders, including:

●     regulatory announcements

●     annual and interim reports

●     corporate presentations

●     company information

●     interviews with the Company’s directors

●     corporate research on N4 Pharma

Investor Hub also provides an interactive online experience allowing Company’s stakeholders to comment on and ask the N4 Pharma team questions via a portal which will be monitored.

To sign up for the N4 Pharma Investor Hub:

1.    Visit investors.n4pharma.com.

2.    Follow the prompts to sign up for an investor hub account.

3.    Complete your account profile.

N4 Pharma’s CEO and Founder, Nigel Theobald commented:

“At N4 Pharma, we have always encouraged our shareholders to engage with us. We see Investor Hub as an effective platform upon which to further enable our shareholders, and potential shareholders to interact with N4 Pharma. Investor Hub will give us a platform to collate all our video material, information and insights about our activities and plans in one place. We encourage our stakeholders to trial Investor Hub and to provide feedback.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    Join N4 Pharma Plc for a pre-recorded webinar on their recent Collaboration Agreement with SRI International Inc. Available on 7 May 2024 at 10:00 BST.
    N4 Pharma Plc partners with SRI International to combine Nuvec® with FOX Three MGS, aiming to enhance nucleotide therapies for cancer and vaccines.
    N4 Pharma Plc (LON:N4P) unveils its audited results for 2023, showcasing advancements in its innovative Nuvec® delivery system for cancer treatments and vaccines.
    N4 Pharma Plc (LON:N4P) updates on successful oral delivery research for Nuvec® system, showing potential for cancer treatment and vaccines. CEO Nigel Theobald shares insights.
    N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec® delivery system for cancer treatments.
    N4 Pharma Plc announces the granting of a patent for its Nuvec® delivery system in India, adding to its global portfolio of granted patents.

      Search

      Search